KEYLearning: MDT Collaboration and Optimising Patient Care

KEYLearning: MDT Collaboration and Optimising Patient Care

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

This module of bite sized videos has been created to highlight the importance of collaboration, sharing of knowledge and experience and how the uro-oncology MDT team co-create the right management for the individual patient.

Introduction

Please use the tabs below to navigate through the module.

Upon watching all videos there are some questions for you to reflect on, which should take around 20 minutes.

We estimate the module will take roughly an hour to complete, and upon completion (if logged in) a CPD certificate will become available and can be downloaded by clicking the button below the accordions.

• The importance of
  collaboration in a
  uro-oncology MDT
• Co-creating a treatment
  plan for patients with
  renal cell carcinoma,
  in a uro-oncology MDT
• Managing diarrhoea
  with dose reduction
  and treatment
  interruption
• Managing transaminitis
  with steroids in a
  patient with intermediate
  risk advanced RCC
• Treatment of advanced
  RCC in a patient with
  liver and bone metastasis
• Questions for
  self-reflective
  learning

The importance of collaboration in a uro-oncology MDT

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Length: 8:51 | This video is best viewed in full screen, using the button in the bottom right

Co-creating a treatment plan for patients with renal cell carcinoma, in a uro-oncology MDT

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Length: 19:15 | This video is best viewed in full screen, using the button in the bottom right

Managing diarrhoea with dose reduction and treatment interruption

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Length: 02:42 | This video is best viewed in full screen, using the button in the bottom right

Prof. Tom Powles presents a case study of a 72 year old male who started on KEYTRUDA in combination with axitinib for advanced renal cell carcinoma, 18 months post nephrectomy. Prof. Powles explains the steps he took to manage the grade 1 diarrhoea.

Patient characteristics
IMDC Risk:	Favourable
Age:	72
Gender:	Male
ECOG score:	1
Patient history:	Heavy smoker, osteoarthritis, controlled hypertension

Managing transaminitis with steroids in a patient with intermediate risk advanced RCC

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Length: 02:36 | This video is best viewed in full screen, using the button in the bottom right

Prof. Tom Powles presents a case study of a 32 year old female who started on KEYTRUDA in combination with axitinib, less than a year after an advanced renal cell carcinoma diagnosis. Prof. Powles explains how transaminitis was managed.

Patient characteristics
IMDC Risk:	Intermediate
Age:	32
Gender:	Female
ECOG score:	1
Patient history:	Irritable bowel disease, 3 month history of haematurea

Treatment of advanced RCC in a patient with liver and bone metastasis

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Length: 02:06 | This video is best viewed in full screen, using the button in the bottom right

Prof. Tom Powles presents his treatment decision for a 45 year old male who started on KEYTRUDA in combination with axitinib, 6 months post nephrectomy for rapidly progressing advanced renal cell carcinoma.

Patient characteristics
IMDC Risk:	Poor
Age:	45
Gender:	Male
ECOG score:	1
Patient history:	Nil of note (marathon runner)

Questions for self-reflective learning

We encourage you to digest the content in the videos by reflecting on the following questions. We estimate this should take around 20 minutes.

Thinking about your own cross functional MDT, what opportunities are there for informal communication and reflective team learning?

How do you identify and manage adverse events with prescribing combination therapies?

How can clinicians support patients to recognise and report adverse events to ensure early intervention management and initiate adverse event protocols?

Adverse events should be reported. Adverse event reporting forms and information can be found at the bottom of this page.

Download your Certificate

Reference

1. KEYTRUDA Summary of Product Characteristics.

Supporting documentation

Prescribing Information and SmPC (Great Britain) & Prescribing Information and SmPC (Northern Ireland) 
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website